Lundbeckfonden Ventures News

Lund, Sweden, 08:30 CET, 21 June 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, today provides an update on the US orders of CERAMENT BVF. Following BONESUPPORT’s decision to set up its own distribution network in the US and terminate its current exclusive distribution agreement, as announced 17 May...
SAN DIEGO – June 7, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that Amplyx and its collaborators will be participating in and presenting at two scientific conferences in the upcoming weeks. Presentations will focus on the company’s lead drug candidate, APX001, which is currently in development for the...
BURLINGTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that, on May 30, 2018, the Company received a letter from the U.S. Food and...
SAN DIEGO – June 5, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the company’s president and chief executive officer, Ciara Kennedy, Ph.D., will participate in a panel at the 2018 BIO International Convention, taking place at the Boston Convention and Exhibition Center June 4-7, 2018. Amplyx also announced...
Lund, Sweden, 08:00 CET, 29 May 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces plans to expand its sales organization in Europe by employing a further 13 sales representatives in its key markets in 2018. The objective is to significantly increase the market penetration of its antibiotic-eluting products...
Lund, Sweden, 13.00 CET, 24 May 2018 – BONESUPPORT, announces an agreement with Collagen Matrix, Inc. that will allow it to expand its US offering with products that are complementary to CERAMENT BVF. BONESUPPORT will start selling and marketing selected Collagen Matrix bone graft substitute products under its own brand name, and through its own US distribution...
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and tolerability of SPR741 when co-administered with b-lactam antibiotics and continues to build on safety profile observed in prior clinical study SPR206 IND-enabling studies demonstrate potential for wide therapeutic margins and broad antimicrobial spectrum...
Lund, Sweden, 13:00 CET 22 May 2018 Today, on 22 May 2018, an annual shareholders’ meeting was held in BONESUPPORT HOLDING AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority. Resolution on adoption of accounts and allocation of the company’s result The annual shareholders’ meeting resolved to...
DECO Study to Explore Dosing Regimen with Higher ICON-1 Dose South San Francisco, CA – May 16, 2018 – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor (TF) biology into new therapeutics for retinal disease and cancer, announced enrollment of the first patient in its second Phase 2 study...
1 2 3 43

Lundbeckfonden Ventures

News

BONESUPPORT provides update on US orders of CERAMENT BVF
21. June 2018
Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
11. June 2018
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
6. June 2018